title: Ultra-low-dose recombinant human bone morphogenetic protein-2 for 3-level anterior cervical diskectomy and fusion.
abstract: This study evaluated the safety of 3-level anterior cervical diskectomy and fusion (ACDF) with ultra-low-dose recombinant bone morphogenetic protein-2 (rhBMP-2). Thirty-seven consecutive patients with cervical spondylotic myelopathy who were treated with 3-level ACDF and rhBMP-2 were evaluated. Complications such as airway or cervical swelling or hematoma were not observed. The rate of dysphagia was no different at 1, 2, and 6 months postoperatively compared with reports in the literature without rhBMP-2. There were significant improvements in VAS neck/arm pain, Oswestry Neck Disability Index, and cervical lordosis. The use of ultra-low-dose rhBMP-2 for 3-level ACDF may be efficacious for surgically addressing 3-level spondylotic myelopathy.
authors.forename: Sina
authors.initials: S
authors.lastname: Pourtaheri
authors.forename: Ki
authors.initials: K
authors.lastname: Hwang
authors.forename: Michael
authors.initials: M
authors.lastname: Faloon
authors.forename: Kimona
authors.initials: K
authors.lastname: Issa
authors.forename: Samuel J
authors.initials: SJ
authors.lastname: Mease
authors.forename: Daniel
authors.initials: D
authors.lastname: Mangels
authors.forename: Kumar
authors.initials: K
authors.lastname: Sinha
authors.forename: Arash
authors.initials: A
authors.lastname: Emami
mesh_terms: D000328:Adult; D000368:Aged; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017586:Diskectomy / Q000009:adverse effects* / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D013123:Spinal Fusion / Q000009:adverse effects* / Q000379:methods; D055009:Spondylosis / Q000601:surgery*; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D055396:Bone Morphogenetic Protein 2; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2